Department of Health
Latest recommendation updates
- ATAGI recommendations on use of
Recent ATAGI considerations
On Wednesday 24 August 2022, ATAGI met to consider the latest developments relating to COVID-19 immunisation. As of 22 August, of COVID-19 vaccines have been administered in Australia.
Novavax COVID-19 vaccination for children aged 12-17 years
On 28 July 2022 the Therapeutic Goods Administration (TGA) provisionally approved Nuvaxovid (Novavax) COVID-19 vaccine (Biocelect Pty Ltd/Novavax Inc) for use in adolescents aged 12-17 years.
ATAGI has evaluated data on immunogenicity, efficacy, safety, and in international settings to make recommendations on the use of Novavax COVID-19 vaccine in this age group.
/Media Release. View in full .
